Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese Association for Research on the Thymus Database Study
- PMID: 25565590
- DOI: 10.1002/cncr.29166
Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese Association for Research on the Thymus Database Study
Erratum in
-
Erratum: Omasa M, Date H, Sozu T, Sato T, Nagai K, Yokoi K, Okamoto T, Ikeda N, Tanaka F, and Maniwa Y, and the Japanese Association for Research on the Thymus. Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: The Japanese Association for Research on the Thymus Database Study. Cancer. doi: 10.1002/cncr.29166.Cancer. 2015 Jun 15;121(12):2102. doi: 10.1002/cncr.29287. Epub 2015 Feb 3. Cancer. 2015. PMID: 26057775 No abstract available.
Abstract
Background: The efficacy of postoperative radiotherapy (PORT) for thymic epithelial tumors is still controversial. Using the Japanese Association for Research on the Thymus (JART) database, this study was aimed at clarifying the efficacy of PORT for Masaoka stage II and III thymic carcinoma and thymoma.
Methods: The JART database registered the records of 2835 patients collected from 32 Japanese institutions from 1991 to 2010. Thymic carcinoma and thymoma at stage II or III were extracted. The efficacy of PORT with respect to relapse-free survival (RFS) and overall survival (OS) was evaluated with the Kaplan-Meier method and Cox regression analysis.
Results: There were 1265 patients in all: 155 thymic carcinoma cases (12.3%) and 1110 thymoma cases (87.7%). Eight hundred ninety-five (70.8%) were at stage II, and 370 (29.2%) were at stage III. Four hundred three cases (31.9%) underwent PORT. PORT for stage II and III thymic carcinoma was associated with increasing RFS (hazard ratio, 0.48; 95% confidence interval, 0.30-0.78; P = .003) but was not associated with OS (hazard ratio, 0.94; 95% confidence interval, 0.51-1.75; P = .536). PORT for stage II and III thymoma was not associated with RFS or OS (P = .350). A subgroup analysis of stage III thymoma showed no factor associated with the efficacy of PORT.
Conclusions: In this study, PORT did not increase RFS or OS for stage II or III thymoma but increased RFS for stage II and III thymic carcinoma.
Keywords: Masaoka stage II; Masaoka stage III; adjuvant radiotherapy; postoperative radiotherapy; relapse-free survival; thymic carcinoma; thymoma.
© 2015 American Cancer Society.
Comment in
-
Postoperative radiotherapy: not all thymic malignancies are created equal.Cancer. 2015 Apr 1;121(7):972-4. doi: 10.1002/cncr.29164. Epub 2015 Jan 6. Cancer. 2015. PMID: 25565462 No abstract available.
Similar articles
-
The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma.J Thorac Oncol. 2017 Apr;12(4):734-744. doi: 10.1016/j.jtho.2017.01.002. Epub 2017 Jan 25. J Thorac Oncol. 2017. PMID: 28126540
-
[Role of Postoperative Radiotherapy for Stage I/II/III Thymic Tumor - Results of the ChART Retrospective Database].Zhongguo Fei Ai Za Zhi. 2016 Jul 20;19(7):465-72. doi: 10.3779/j.issn.1009-3419.2016.07.09. Zhongguo Fei Ai Za Zhi. 2016. PMID: 27339724 Free PMC article. Chinese.
-
Adjuvant radiotherapy for thymic epithelial tumor: treatment results and prognostic factors.Am J Clin Oncol. 2007 Aug;30(4):389-94. doi: 10.1097/COC.0b013e318042d566. Am J Clin Oncol. 2007. PMID: 17762439
-
Postoperative Radiotherapy for Completely Resected Masaoka/Masaoka-Koga Stage II/III Thymoma Improves Overall Survival: An Updated Meta-Analysis of 4746 Patients.J Thorac Oncol. 2021 Apr;16(4):677-685. doi: 10.1016/j.jtho.2020.12.023. Epub 2021 Jan 27. J Thorac Oncol. 2021. PMID: 33515812
-
Postoperative radiotherapy for completely resected thymoma and thymic carcinoma: A systematic review and meta-analysis.PLoS One. 2024 Aug 30;19(8):e0308111. doi: 10.1371/journal.pone.0308111. eCollection 2024. PLoS One. 2024. PMID: 39213310 Free PMC article.
Cited by
-
Clinical Outcomes of Thymic Carcinoma: The Role of Radiotherapy Combined with Multimodal Treatments.Cancers (Basel). 2023 Apr 12;15(8):2262. doi: 10.3390/cancers15082262. Cancers (Basel). 2023. PMID: 37190190 Free PMC article.
-
The role of postoperative radiotherapy in stage II and III thymoma: a Korean multicenter database study.J Thorac Dis. 2020 Nov;12(11):6680-6689. doi: 10.21037/jtd-20-1713. J Thorac Dis. 2020. PMID: 33282369 Free PMC article.
-
Radiotherapy for thymic epithelial tumours: a review.Transl Lung Cancer Res. 2021 Apr;10(4):2088-2100. doi: 10.21037/tlcr-20-458. Transl Lung Cancer Res. 2021. PMID: 34012817 Free PMC article. Review.
-
Thymic Carcinoma Management Patterns among International Thymic Malignancy Interest Group (ITMIG) Physicians with Consensus from the Thymic Carcinoma Working Group.J Thorac Oncol. 2017 Apr;12(4):745-751. doi: 10.1016/j.jtho.2016.11.2219. Epub 2016 Nov 19. J Thorac Oncol. 2017. PMID: 27876674 Free PMC article.
-
The role of postoperative radiotherapy for invasive thymic epithelial tumors: a single-center experience.J Thorac Dis. 2025 Apr 30;17(4):2000-2013. doi: 10.21037/jtd-24-1805. Epub 2025 Apr 24. J Thorac Dis. 2025. PMID: 40400973 Free PMC article.